Vivera Pharmaceuticals, Inc.

  • Home
  • About Us
    • Executive Team
    • Advisory Board
    • Ambassador Board
    • Professional Team
  • Divisions
    • Advanced Diagnostics
    • Medical Device
    • Medical Technologies
    • Pharmaceuticals
    • Licensing & Distribution
  • Press
    • Press Releases
    • Media Coverage
    • Promotional Videos
  • Products
    • Medical Products
    • OTC Products
    • Clinical Trials
  • Contact

Press Releases

Press

Press

  • Press Releases
  • Media Coverage
  • Promotional Videos

Vivera Pharmaceuticals files patents for future at-home antibodies testing; approvals will expedite consumer access

Jun 9, 2020

Vivera Pharmaceuticals Supports Telemedicine and Home Testing for COVID-19

Apr 17, 2020

Vivera Pharmaceuticals Chief Medical Officer calls for rapid expansion of COVID-19 testing

Apr 8, 2020

Vivera Pharmaceuticals Has Committed Up to $15 Million in COVID-19 Diagnostic Tests to be Donated

Apr 7, 2020

Vivera Pharma CEO Exposes Questionable Practices of Importers of Fraudulent Chinese COVID-19 Tests

Apr 3, 2020

Coushatta Tribe and Vivera Pharmaceuticals Join Forces in Fight Against COVID-19

Mar 24, 2020

Vivera Pharmaceuticals Announces New Rapid COVID-19 Test

Mar 20, 2020

Vivera Pharmaceuticals Names R.J. Demman Chief Operations Officer

Feb 20, 2020

Andrea Millsap Joins Vivera Pharmaceuticals As National Sales Director

Jan 7, 2020

Vivera Pharmaceuticals Enters Agreement to Conduct Clinical Study With Parexel Biotech

Dec 3, 2019
    • 1
    • 2
    • 3
    • 4
    • 5
    Next

    Investor Relations and Media Inquiries:

    Investor Inquiries:
    investorrelations@viverapharma.com

    Media Inquiries:
    press@viverapharma.com

    Forward-looking and cautionary statements:

    The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of Vivera Pharmaceuticals securities in the United States. This news release may contain "forward-looking information" as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera Pharmaceuticals, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera Pharmaceuticals and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera Pharmaceuticals future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera Pharmaceuticals' expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera Pharmaceuticals, reference should be made to Vivera Pharmaceuticals continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera Pharmaceuticals CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. Vivera Pharmaceuticals does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release.

    • Home
    • About Us
    • Divisions
    • Press
    • Products
    • Contact
    Vivera Pharmaceuticals, Inc.
    Instagram LinkedIn YouTube
    © 2021 Vivera Pharmaceuticals, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap
    English Español 中文 العربية Français Pусский